LUCID logo header


A multi-centre prospective trial for lung cancer screening


Early detection saves lives

LuCID overview infographics

Funded by an NHS development contract, Owlstone Medical is conducting research into the diagnosis of lung cancer by measuring volatile organic compounds (VOCs) in patients' exhaled breath. Phase I of the project is complete and Phase II is underway.

We established that Owlstone Medical’s FAIMS technology can detect biomarkers with a promising sensitivity: detecting at threshold concentrations ten times lower than previously reported. An initial analysis identified that successful introduction of a lung cancer screening programme using ReCIVA and FAIMS could could save approximately 3,200 lives per year and £82M in treatment costs in the UK alone.

The second phase of the study is funded by a £1.1m SBRI grant from the UK National Health Service and aims to validate detection of lung cancer biomarker by FAIMS in clinical practice. The final phase of the study will be a population based screening trial. You can read the LuCID infographic here.

Lonestar enables FAIMS-driven detection of disease biomarkers in clinical samples

learn more about Lonestar
Lonestar product testimonial 2

Taking part

Taking part in the clinical trial

To be able to take part in this study the patient must be under clinical suspicion of having lung cancer, be aged 18 or older and agree to provide written consent to taking part in the clinical trial. Patients who attend a clinic that is registered for the trial may be invited to take part; it is not possible to volunteer for this study.

  • 2015.00
    Start of the LuCID clinical trial
  • 1760.00
    Total numbers of participants to date
  • 26.00
    Total number of clinical sites the clinical trial is taking place in
  • 4000.00
    Patients taking part
Owlstone team member using ReCIVA

What to expect if you are selected

A nurse will explain the study to you and answer any of your questions. If you are happy to proceed, the nurse will fill in a questionnaire with information about you and your health and take a sample of breath using Owlstone Medical’s ReCIVA breath sampler. This sample will be analysed by Owlstone Medical in its Cambridge Breath Biopsy Laboratory. These results, along with other information that we get from your doctor such as whether the tumour is cancer, will be used to develop a new test to screen for lung cancer.

Get in touch for more information

LuCID in the news

Study protocol

Summary of the protocol

  • Design

    An international multi-centre prospective study designed to evaluate breath analysis in a clinical setting

  • Primary outcome

    To evaluate the diagnostic accuracy (sensitivity and specificity) of a breath test for lung cancer

  • Patient eligibility

    Patients, aged 18 or older, in secondary care with a clinical suspicion of lung cancer

  • What to expect

    After a briefing and agreeing to take part a nurse will take a sample of breath using ReCIVA

  • Breath analysis

    Analysed using Owlstone Medical's propriety Field Asymmetric Ion Mobility Spectrometry technology

  • Data analysis

    The test uses patient information and breath biomarkers to predict whether a patient has lung cancer

Collect reliable and reproducible breath samples for VOC biomarker analysis

Discover ReCIVA
Image of ReCIVA Breath Sampler device
LuCID hospital sites map

Study team

The far reaching scale of the clinical trial

Led by Dr Robert Rintoul at Papworth Hospital near Cambridge UK, the study investigators are recognised experts in lung cancer at some of Europe’s leading hospitals and clinics. Clinical sites across 5 different countries are participating in the clinical trial.

By investing in Owlstone Medical you can help make this happen sooner.

We are on a mission to save 100,000 lives. By investing in Owlstone Medical you can support our research and help make this happen sooner.

Discuss investment opportunities